Loading insider details...
Beta
Latest Form 4 (Jun 8, 2026): Grant/Award of 4,000 TNGX shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2026 | Tango Therapeutics, Inc. (TNGX) | Grant/Award | 4,000 | n/a |
| Mar 11, 2026 | Aligos Therapeutics, Inc. (ALGS) | Grant/Award | 37,485 | n/a |
| Jul 18, 2025 | Aligos Therapeutics, Inc. (ALGS) | Grant/Award | 40,185 | n/a |
| Jun 9, 2025 | Tango Therapeutics, Inc. (TNGX) | Grant/Award | 6,250 | n/a |
| Mar 4, 2025 | Aligos Therapeutics, Inc. (ALGS) | Grant/Award | 47,271 | n/a |
| Sep 6, 2024 | Aligos Therapeutics, Inc. (ALGS) | Grant/Award | 10,880 | n/a |
| Jun 7, 2024 | Tango Therapeutics, Inc. (TNGX) | Grant/Award | 6,250 | n/a |
| Mar 4, 2024 | Aligos Therapeutics, Inc. (ALGS) | Grant/Award | 308,940 | n/a |
| Feb 28, 2024 | Aligos Therapeutics, Inc. (ALGS) | Disposition to Issuer | 176,237 | n/a |
| Sep 12, 2023 | Aligos Therapeutics, Inc. (ALGS) | Grant/Award | 48,000 | n/a |